Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| To date, LSDA1 has demonstrated favorable safety, tolerability, and activity to enhance delivery of standard of care chemotherapy for patients with metastatic pancreatic cancer |
| That said, we are extremely grateful to our investigators and especially to those patients participating in LSTA1 clinical trials around the world |
| As it relates to BOLSTER-- BOLSTER is actually on track to reach the enrollment goal of completion by the end of 2024, and we're quite pleased with that |
| But the CFDA has done a pretty good job of replicating many of the accelerated pathways of US, FDA |
| But you can see the model there of how a product that can be used in combination with a variety of other products can be marketed in a variety of different ways and can achieve great commercial success |
| We remain grateful for your continued interest and support |
| CENDIFOX, the Phase 1b/2a open-label trial in the United States of LSDA1 in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon, and appendiceal cancers continues to make steady progress, with enrollment completion expected by the end of the second quarter of 2024 |
| As previously reported, a positive outcome from the planned interim futility analysis was announced by the study's Independent Data Safety Monitoring Committee, which recommended continuation of the study without modification |
| This action by the FDA not only highlights the unmet medical need, but also recognizes the potential of LSTA1 to benefit patients in this indication |
| It actually has more of the shape of a hockey stick, and we're finally on the upslope of that curve and moving things very, very nicely |
| Along with our collaborators, we have also amassed significant non-clinical data demonstrating enhanced delivery of a range of anti-cancer therapy modalities, including immunotherapies and RNA-based therapeutics |
| And I believe that their program is designed to take maximum advantage of the possibility of an accelerated approval pathway |
| As we have previously reported, we have both preclinical and early clinical data in humans that we believe demonstrates the potential of LSTA-1 to become an integral part of a revised standard of care treatment regimen for many difficult to treat cancers |
| BOLSTER continues to make steady progress, and enrollment completion is expected by the end of 2024 |
| During 2023, our first full year as Lisata, we made notable progress advancing our clinical development programs, targeting several advanced solid tumors using LSTA-1, our lead product candidate, in combination with multiple anti-cancer agents of differing modalities |
| Stay well and have a good evening |
| In addition, we are excited to report that full enrollment of ASCEND has been achieved, and we expect top-line data from the 98 patients assigned to cohort A to be reported in the fourth quarter of 2024, followed by the complete data set of all 158 patients to be available by mid-2025 |
| David Mazzo Well, WARPNINE is a philanthropic foundation in Australia dedicated to the improvement and the rapid accessibility of patients to novel treatments for gastrointestinal cancers of all types |
| This binding activates the C-end Rule active transport pathway, which ferries anti-cancer drugs more efficiently into solid tumors |
| And good afternoon |
| So they're actually pretty efficient at getting to full funding, and it's because they tap a network of philanthropic organizations and individuals within their region of the world, mostly Australia and New Zealand, who are very interested in supporting the cause |
| Lower annual stockholder meeting expenses, and a decrease in directors and officers insurance premiums |
| And again, thank you all for participating in today's call |
| Generating meaningful clinical data as efficiently as possible is critically important in this field, and I can assure you that our entire organization has this goal top of mind in everything we do |
| Importantly, as recently announced, LSTA1 has been granted orphan drug designation by the US |
| To summarize, 2023 was a year marked by the honing of our LSTA1 development efforts in keeping with our strategic imperatives of advancing LSTA1 rapidly toward registration in mPDAC, as well as demonstrating the broad application of LSTA1 in combination with a variety of anti-cancer agents for the treatment of numerous solid tumor types |
| Peter Enderlin That's very interesting and it makes a lot of sense |
| For 2024, more than ever-- we are focused on efficient and timely study execution with the goal of getting to meaningful clinical data readouts as soon as possible |
| Good afternoon |
| As it relates to regional contributions, so far the US has been the greatest contributor to enrolment, but that's mostly because many of our European sites will only really be coming online in the month of March, and so we expect to see a significant contribution from the European theater starting in the second quarter of this year |
| Statement |
|---|
| This, coupled with the fact that most anti-cancer therapies are not efficient in targeting only cancer tissue, defines the major challenge in maximizing effectiveness and safety in the treatment of solid tumors |
| Despite advances in cancer therapy today, many solid tumors remain difficult to treat effectively |
| Overall, net losses were $20.8 million and $54.2 million for the years ended December 31, 2023, and 2022, respectively |
| Many solid tumors also present a hostile tumor microenvironment, or TME, which suppresses a patient's immune system and makes it less effective in fighting cancer |
| Our platform technology is designed to address major impediments to the successful treatment of advanced solid tumors in an environment of increasing pharmacoeconomic pressures |
| Representing a decrease of approximately $1.2 million, or 8.3% |
| Representing a decrease of approximately $300,000, or 2.5% |
| Excluding the in-process research and development expense of $30.4 million associated with the merger of Cend Therapeutics and our predecessor company, Caladrius Biosciences, forming Lisata Therapeutics, operating expenses decreased by $1.5 million, or 5.5%, compared to the year ended December 31, 2022 |
| Representing a decrease of $31.9 million, or 55.4% |
Please consider a small donation if you think this website provides you with relevant information